kerx

Keryx Biopharma (Nasdaq: KERX) 2.9% LOWER; filed for a $100 million mixed securities shelf. Monolithic Power Systems (Nasdaq: MPWR) 2.1% LOWER; announced that Rick Neely has resigned from his position as Senior Vice President and Chief Financial Officer to pursue another opportunity at a private company.

Meera Rao will assume the position and responsibilities as MPS's Chief Financial Officer effective immediately.

Annaly Capital Management, Inc.

National Dentex Corporation (NASDAQ: NADX) 68% HIGHER; entered into a definitive agreement and plan of merger to be acquired by GDC Holdings, Inc., which is a holding company of GeoDigm Corporation, a technology based manufacturing and laboratory company and a portfolio company of Welsh, Carson, Anderson & Stowe XI, L.P.

Under the terms of the merger agreement, National Dentex’s shareholders will receive $17.00 in cash for each share of National Dentex common stock they hold.

Anchor BanCorp Wisconsin Inc.

Grubb & Ellis (NYSE: GBE) 40% HIGHER; continuing higher today on what appears to be a technical breakout.

Since crossing over the $1 level, shares of GBE have jumped nearly 70% on very heavy volume. Keryx Biopharmaceuticals (Nasdaq: KERX) 23.3% HIGHER; announced results of the Open Label Extension trial of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

Hi-Shear Technology Corporation (NYSE: HSR) 58.1% HIGHER; Chemring Group PLC entered into a conditional agreement to acquire the entire issued stock capital of for a cash consideration of $19.18 per share equating to $132 million.

American Technology (Nasdaq: ATCO) 46.2% HIGHER; surging on extremely heavy volume: already traded 3.17 million shares, compared to its average daily volume of 157,000.

Not hearing any company-specific news.

Patriot Capital Funding, Inc.

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) 98.6% HIGHER; At ASCO yesterday, Keryx announced data on the clinical activity of KRX-0401 (perifosine), the Company's Akt-inhibitor for cancer, in combination with capecitabine as a treatment for advanced colon cancer. Click here for the full report.

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) 52.8% HIGHER; reports Q1 EPS of $0.01, 9 cents better than the analyst estimate of ($0.08) and compared to a loss of $0.79 in the same quarter last year.

Revenue for the quarter was $3.3 million, versus the consensus of $320K. Lear Corporation (NYSE: LEA) 20% LOWER; reports Q1 loss of $3.42, versus the analyst estimate of ($1.73).

Revenue for the quarter was $2.2 billion, versus the consensus of $2.15 billion. Power Medical Intervention, Inc.